

Invitra AT™

Amniotic Tissue Product Description

Invitra AT™ is a biological acellular product derived from human amnion. Amniotic tissue is comprised of an extracellular matrix that forms a natural scaffold. Amniotic tissue has a series of anti-inflammatory, anti-bacterial, anti-viral properties as well as low immunogenicity. This natural scaffold works as a physical barrier that can contain cells to an affected area by maintaining adhesion of cells.

Invitra AF™

Amniotic Fluid Product Description

Invitra AF™ is a biological acellular product derived from the human amnion. Amniotic fluid is rich in growth factors and cytokines including growth factor (EGF), transforming growth factor alpha (TGF alpha), transforming growth factor beta-1, and insulin-like growth factor 1 (IGF1). Importantly, amniotic fluid contains factors related to the innate immune system including a spectrum of antimicrobials effective against bacteria, fungi, protozoa, and viruses.

Dedication to Excellence

Invitrx Therapeutics, headquartered in Orange County California is a global research-based biotechnology company with over 15 years of product development industry experience. Established in 2003, Invitrx Therapeutics has been a leading pioneer in Regenerative Stem Cell Therapies.

Invitra Amniotic Fluid (pg/ml)

Anti-inflammatory

IL-1ra	2,971.10
IL-10	23
HGF	27,403.80
TNF RII	64,122.60
TGF β-1	457.5

Wound Healing

VEGF	144.4
TGF β-1	457.5
IL-6	2,928.90
PDGF-BB	57
HGF	27,403.80
bFGF	356.6
ANG-1	19,376.50
FGF-7	2,546.50

Homeostatic Cytokines

IL-2	28.6
IL-7	137.9
IL-15	0
TIMP-2	51,298.50
Lipocalin-2	13,074.60

Growth Factors

ANG-1	19,376.50
bFGF	356.6
BMP-7	1,967.30
TGF β-1	457.5
VEGF	144.4

Quality Assurance

Invitra AT™ & AF™ is processed from donated umbilical cords from full term deliveries. All donors are Pre-screened and undergo comprehensive testing that includes:

- Behavioral risk assessment
- Physical assessment
- Donor medical history
- Communicable disease testing

Infectious disease testing is performed at a certified laboratory in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493.